ArticleCancer reports (Hoboken, N.J.)2026
Long-Term Patient-Reported Outcomes and Dosimetric Predictors of Quality of Life After Curative-Intent Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: A Cross-Sectional Study.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiation therapy (RT) is central to curative treatment for oropharyngeal squamous cell carcinoma (OPSCC) but may cause late side effects that can adversely impact quality of life (QOL). As OPSCC treatment becomes more personalised, clinically meaningful QOL endpoints and their predictors are increasingly important.
aimsTo assess long-term QOL, treatment regret, and predictors of QOL after curative-intent RT for OPSCC. METHODS AND
resultsThis cross-sectional survey included patients with primary OPSCC treated with curative intent RT between 2007 and 2023 at a single tertiary institution. Patients completed validated EORTC QOL questionnaires and additional items assessing perceived health and treatment regret. Survival outcomes were estimated using Kaplan-Meier methods, and compared by p16 status using log-rank test. QOL scores were analysed as continuous variables using univariate and multivariable linear regression models, with prespecified dosimetric predictors tested against clinically corresponding EORTC QOL-HN43 symptom scales and adjusted for multiple comparisons. Of the 344 patients treated, 274 (80%) had p16-positive disease. At median follow of 7.7 years, 5-year overall survival was 90% for p16-positive versus 52% for p16-negative disease, and disease-free survival 89% versus 72%. Of 232 patients contacted, 186 (80%) completed the QOL survey at median 6.3 years after RT. 173 (93%) reported no treatment regret regarding RT. Mean global health status was 81.3/100, while dry mouth/sticky saliva was the most affected domain (mean 41.9/100). On multivariable analysis, older age was associated with worse global health status (-4.9 points per 10 years, p = 0.001) and higher contralateral mean parotoid dose with worse dry mouth/sticky saliva scores (10.1 points per 10 Gy, 95% CI: 3.7 to 16.5, p = 0.002). Chemotherapy and prior surgery were not associated with any domain.
conclusionLong-term survivors of OPSCC reported favourable global QOL and little treatment regret after RT. However, dry mouth/sticky saliva remained a substantial burden, and more likely with higher contralateral parotid mean dose. These findings support ongoing contralateral parotid sparing and consideration of unilateral neck irradiation when oncologically appropriate, while recognising the cross-sectional cohort and need for rigorous prospective studies in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.